Immutep director reports share and rights holdings
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership.
Rhea-AI Filing Summary
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership. The filing shows direct holdings of Ordinary Shares, including 11,353,764 shares in one entry and 170,610 shares in another, which are represented by American Depositary Shares.
The filing also lists performance rights over Ordinary Shares with a zero exercise price. Footnotes state that blocks of 900,000 performance rights are scheduled to vest on December 1 of 2026, 2027 and 2028, with additional performance rights vesting only if Dr. Triebel meets specified key performance indicators at each applicable vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Triebel Frederic Joseph Daniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Performance rights (right to receive) — 2,700,000 contracts (Direct);
Ordinary Shares — 11,524,374 shares (Direct)
Footnotes (4)
- F1. Such Ordinary Shares are represented by American Depositary Shares.
- F2. Granted on December 5, 2024. 900,000 performance rights will vest on December 1, 2026 and the vesting of the remaining 1,800,000 performance rights is dependent on Dr Triebel achieving key performance indicators at the applicable vesting date.
- F3. Granted on December 5, 2024. 900,000 performance rights will vest on December 1, 2027 and the vesting of the remaining 900,000 performance rights is dependent on Dr Triebel achieving key performance indicators at the applicable vesting date.
- F4. Granted on December 5, 2024. 900,000 performance rights will vest on December 1, 2028 and the vesting is dependent on Dr Triebel achieving key performance indicators at the applicable vesting date.
Key Figures
Ordinary Share holding entry 1: 11,353,764 shares
Ordinary Share holding entry 2: 170,610 shares
Performance rights tranche 1: 900,000 underlying shares
+4 more
7 metrics
Ordinary Share holding entry 1
11,353,764 shares
Direct ownership of Ordinary Shares as of the Form 3
Ordinary Share holding entry 2
170,610 shares
Additional direct Ordinary Shares as of the Form 3
Performance rights tranche 1
900,000 underlying shares
Performance rights vesting on December 1, 2026
Performance rights tranche 2
900,000 underlying shares
Performance rights vesting on December 1, 2027
Performance rights tranche 3
900,000 underlying shares
Performance rights vesting on December 1, 2028
Exercise price of performance rights
$0.00 per share
Conversion or exercise price for performance rights
Performance rights expiration
December 5, 2029
Expiration date for listed performance rights
Key Terms
Performance rights, Ordinary Shares, American Depositary Shares, key performance indicators
4 terms
Performance rights financial
"security_title: "Performance rights (right to receive)""
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
key performance indicators financial
"dependent on Dr Triebel achieving key performance indicators at the applicable vesting date."
Key performance indicators are specific measurements used to track how well a person, team, or organization is achieving its goals. They act like report cards, providing clear signs of progress or areas needing improvement. For investors, KPIs help assess the health and future potential of a business by highlighting its most important strengths and challenges.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the IMMUTEP (IMMP) Form 3 filing report for Dr. Frederic Triebel?
The Form 3 reports Dr. Frederic Triebel’s initial beneficial ownership in IMMUTEP. It shows direct holdings of Ordinary Shares and multiple tranches of performance rights that may vest between December 2026 and December 2028, subject in part to achieving key performance indicators.
When were Dr. Triebel’s IMMUTEP performance rights granted and when can they vest?
Footnotes state the performance rights were granted on December 5, 2024. Portions of 900,000 performance rights are scheduled to vest on December 1, 2026, 2027 and 2028, and vesting of additional rights depends on Dr. Triebel meeting key performance indicators at those vesting dates.
Are IMMUTEP performance rights for Dr. Triebel subject to conditions?
Yes. While 900,000 performance rights are scheduled to vest on each of December 1, 2026, 2027 and 2028, the footnotes explain that vesting of remaining performance rights in each grant depends on Dr. Triebel achieving specified key performance indicators at the relevant vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
